Jazz Pharmaceuticals director exercises stock options
Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share. After this exercise, he holds 1,183,028 Ordinary Shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
The option was originally granted on August 11, 2016 and had fully vested by August 1, 2017. Following this transaction, no shares remain under the exercised option, and there is no remaining derivative position reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,415 shares exercised/converted
Exercise
3 txns
Insider
Mulligan Seamus
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 3,415 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 3,415 | $138.08 | $472K |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Ordinary Shares — 1,183,028 shares (Direct);
Ordinary Shares — 101,621 shares (Indirect, By Nerano Pharma Lim)
Footnotes (2)
- F1. Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
- F2. This non-qualified stock option was granted on August 11, 2016 and vested over the period from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017.
Key Figures
Shares acquired via option exercise: 3,415 shares
Option exercise price: $138.08 per share
Direct holdings after transaction: 1,183,028 shares
+3 more
6 metrics
Shares acquired via option exercise
3,415 shares
Non-qualified stock option exercised on May 28, 2026
Option exercise price
$138.08 per share
Non-qualified stock option for Ordinary Shares
Direct holdings after transaction
1,183,028 shares
Ordinary Shares held directly after May 28, 2026 exercise
Indirect holdings via Nerano Pharma Limited
101,621 shares
Ordinary Shares beneficially owned through family entity
Exercised option shares remaining
0 shares
Non-qualified stock option position after exercise
Derivative exercises in filing
1 transaction, 3,415 shares
Form 4 transaction summary exerciseCount and exerciseShares
Key Terms
Non-Qualified Stock Option (right to buy), derivative security, beneficially owned, indirect
4 terms
Non-Qualified Stock Option (right to buy) financial
"security_title: "Non-Qualified Stock Option (right to buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficially owned financial
"Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
indirect financial
"ownership_type: "indirect" and nature_of_ownership: "By Nerano Pharma Lim""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did JAZZ director Seamus Mulligan report?
Director Seamus Mulligan reported exercising a non-qualified stock option to acquire 3,415 Jazz Pharmaceuticals Ordinary Shares at $138.08 per share. This is a compensation-related derivative exercise, not an open-market purchase or sale, and increases his directly held share count.
What was the price on the JAZZ stock option exercised by Seamus Mulligan?
The non-qualified stock option exercised by Seamus Mulligan had an exercise price of $138.08 per Jazz Pharmaceuticals Ordinary Share. He exercised options for 3,415 shares, converting this derivative award into directly held equity as reflected in the Form 4 filing data.
What is Nerano Pharma Limited’s role in Seamus Mulligan’s JAZZ holdings?
Nerano Pharma Limited holds 101,621 Jazz Pharmaceuticals shares beneficially owned by Seamus Mulligan and his immediate family. The filing notes this entity is owned and controlled by them, so these shares are reported as indirect ownership attributable to Mulligan on the Form 4.
Were the exercised JAZZ stock options already fully vested?
Yes. The footnote explains the non-qualified stock option was granted on August 11, 2016 and vested from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017, before Mulligan exercised 3,415 shares in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
